ACE-031 Results Timeline: What Studies Measured, and When

What the published ACE-031 record covers

ACE-031 was developed as a soluble activin type IIB receptor fusion protein intended to bind myostatin and related ligands, and that mechanism is described in the nonhuman primate report of ACE-031 in the common marmoset (PMID 41686840). Anyone looking for a "results timeline" needs to know first how thin the human record is: the peer-reviewed human literature consists of a single ascending-dose study in healthy volunteers (PMID 23169607) and one randomized, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy (DMD) that was discontinued early (PMID 27462804). Review articles from 2011 placed myostatin-blockade strategies, including soluble activin receptor approaches, in the broader context of experimental therapy for myopathies (PMID 22277518) and muscular atrophy (PMID 22068480).

Because of that, this page describes what researchers measured and when they measured it, not what any individual should expect. No published study in the verified set followed humans for years, and none reported a long-term efficacy timeline. This page is for educational purposes only and is not medical advice; consult a licensed physician about any compound, condition or symptom.

Timeline at a glance: study design and measurement points

The single-dose human study: measurements after one administration

The earliest human data point in the verified set came from a single ascending-dose study of ACE-031 in healthy volunteers, in which participants received one subcutaneous administration or placebo and were then followed for safety, pharmacokinetics and pharmacodynamic markers (PMID 23169607). The design matters for timeline questions: a single-dose study answers "what is detectable after one exposure," not "what happens after months of repeated exposure." Researchers in that study reported dose-related changes in body composition and in circulating biomarkers in the weeks following the single dose, alongside the safety observations summarized further down this page (PMID 23169607).

Two practical limits follow. First, measurements of lean mass or muscle volume made roughly a month after one dose describe a short observation window, not a trajectory. Second, the study enrolled healthy volunteers, so its timeline cannot be transferred to people with a neuromuscular disease, where baseline muscle physiology differs (PMID 23169607).

The Duchenne trial: planned timepoints versus what actually happened

The most frequently cited human study of ACE-031 was a randomized, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy, in which participants received repeated subcutaneous doses of ACE-031 or placebo (PMID 27462804). The trial's planned endpoints included functional walking capacity and body-composition measures, which is the kind of schedule that would, in principle, generate a results timeline across several months.

That timeline was never completed. Dosing in the trial was stopped early after researchers observed nonmuscle-related adverse events, and the published report described the resulting dataset as limited by that early discontinuation (PMID 27462804). The study reported trends in body composition and walking-distance measures that did not establish a clinical benefit, and the authors framed the findings in the context of the safety signals that ended dosing (PMID 27462804). In other words, the single human trial designed to track outcomes over months was truncated, which is the central reason no durable human efficacy timeline for ACE-031 exists.

Why "the trial was stopped" changes how timelines should be read

• Fewer doses than planned means later scheduled assessments were not collected as designed (PMID 27462804).
• Smaller effective sample at later visits reduces the ability to detect or exclude change at those timepoints (PMID 27462804).
• Safety, not efficacy, drove the decision, so the early stop says nothing about whether longer dosing would have changed functional endpoints (PMID 27462804).

Animal data: what the marmoset work measured

Nonhuman primate work is explicitly animal research and is labeled as such here. A study in the common marmoset reported that ACE-031 increased muscle mass and muscle strength in that species (PMID 41686840); the same work was first posted as a preprint (PMID 41256654). Animal studies typically assess mass and strength after a defined dosing period under controlled conditions, which makes them useful for mechanism but not for predicting a human timeline. Species differences in receptor biology, dosing scale and measurement methods all mean that the interval over which marmosets were assessed does not translate into a human expectation (PMID 41256654).

What "results" meant in these studies

Readers searching for a results timeline often have strength or appearance in mind. The published endpoints were narrower and more technical. Across the verified human record, measurements fell into three families: safety and tolerability observations, body-composition measures such as lean and fat mass, and functional or biomarker endpoints (PMID 23169607, PMID 27462804).

Body-composition endpoints

Body-composition endpoints change on a different schedule than subjective experience. The single-dose study tracked composition and biomarkers after one administration (PMID 23169607), while the Duchenne trial reported lean and fat mass alongside its functional measures before dosing was halted (PMID 27462804). A measured increase in lean mass on an imaging or densitometry endpoint is not the same claim as improved function, and the trial's own functional results did not demonstrate clinical benefit (PMID 27462804).

Functional endpoints

Walking capacity was the functional anchor in the Duchenne trial, and the published report did not establish a functional benefit over placebo within the shortened dosing period (PMID 27462804). Reviews of myostatin-blockade therapy written in the same era discussed the general expectation that increasing muscle mass would not automatically produce proportional functional gains in myopathy (PMID 22277518).

Adverse Events: What Studies Report

Safety observations are the clearest part of the ACE-031 timeline because they are what ended clinical development of the compound in the setting studied. The randomized Duchenne trial reported nonmuscle-related adverse events that led to early discontinuation of dosing, and the published report centers on that safety experience (PMID 27462804). The single ascending-dose study in healthy volunteers likewise reported safety and tolerability findings as a primary focus of the work (PMID 23169607).

Two points follow for anyone reading timeline claims. First, adverse events in the human record appeared within the same short windows in which body-composition changes were being measured, so "early results" and "early safety signals" occupy the same part of the timeline (PMID 27462804). Second, because dosing stopped, there is no published human characterization of what happens with prolonged administration (PMID 27462804).

Timepoints the literature never covered

• Beyond the truncated trial period in Duchenne muscular dystrophy — dosing was stopped early, so longer human follow-up on the planned schedule was not reported (PMID 27462804).
• Repeated dosing in healthy adults — the healthy-volunteer study was a single-dose design (PMID 23169607).
• Athletic or performance populations — no study in the verified set enrolled athletes or examined performance timelines (PMID 23169607, PMID 27462804).
• Durability after stopping — the verified human reports did not characterize how measured changes behaved over an extended washout (PMID 23169607).

How to read timeline claims critically

1. Ask which population. Healthy volunteers and boys with Duchenne muscular dystrophy are different populations with different baselines (PMID 23169607, PMID 27462804).
2. Ask whether the dosing was single or repeated. A single-dose pharmacology study cannot describe a months-long trajectory (PMID 23169607).
3. Ask whether the species is human. Marmoset findings on mass and strength are animal data (PMID 41686840).
4. Ask whether the endpoint was functional. The Duchenne trial's functional findings did not establish benefit within its shortened course (PMID 27462804).
5. Ask whether a review is primary evidence. The 2011 review of myostatin blockade for muscular atrophy summarized a field rather than reporting new trial timepoints (PMID 22068480).

Regulatory and status context

ACE-031 is not an approved medicine in the United States or elsewhere; the clinical program described in the published Duchenne trial did not proceed past the discontinued study, and the compound appears in the literature as an investigational agent (PMID 27462804). Materials sold under this name outside of an approved clinical setting are not evaluated medicines, and nothing on this page describes availability, sourcing or administration. This page is for educational purposes only and is not medical advice; readers with questions about muscle disease or any investigational compound should consult a licensed physician.

Bottom line on the ACE-031 timeline

The honest summary is that the human timeline is short and incomplete: one single-dose study measured safety, pharmacokinetics and body-composition markers after one administration in healthy volunteers (PMID 23169607), one randomized trial in ambulatory boys with Duchenne muscular dystrophy was halted before its planned treatment period concluded because of nonmuscle adverse events (PMID 27462804), and the remaining primary evidence on mass and strength comes from marmosets (PMID 41686840). Any claim that specific changes appear by a specific week in humans goes beyond what these publications reported.

References

• A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers (Muscle & Nerve, 2013)
• Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial (Muscle & Nerve, 2017)
• ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus) (PLoS One, 2026)
• ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) (bioRxiv, 2025)
• [Anti-myostatin antibody therapy for myopathies] (Rinsho Shinkeigaku, 2011)
• [Myostatin blockade therapy for muscular atrophy] (Brain and Nerve, 2011)